Gilead Sciences, Inc. has issued a voluntary recall for approximately 105,000 vials of Veklury (remdesivir) for injection, 100 mg/vial. The recall was initiated after a glass particle was discovered in a vial from the affected lot. Veklury is an antiviral medication used in hospital and clinical settings to treat COVID-19. This recall specifically affects lot number 47035CFA with an expiration date of November 2025.
The administration of an injectable medication containing glass particles can cause local irritation or swelling. In more serious cases, the particles could travel through the bloodstream and cause blood vessel blockages or damage to vital organs such as the lungs or brain.
Quantity: 105,000 vials
Image: Front of Carton and vial, Veklury
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.